Han Sung-hee, Lee Jonghun
Department of Internal Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea.
Korean J Gastroenterol. 2014 Jan 25;63(1):3-10. doi: 10.4166/kjg.2014.63.1.3.
The risk of developing colorectal cancer is increased in patients with inflammatory bowel disease. Surveillance colonoscopy has not been shown to prolong survival and rates of interval cancer are reported to be high. Continuing colonic inflammation has been shown to be important in the development of colorectal cancer and therefore anti-inflammatory agents such as the 5-aminosalicylates and immunomodulators have been considered as potential chemopreventive agents. This review focuses on various chemopreventive agents that have been clearly shown to reduce the risk of colorectal adenoma and cancer in the patients with inflammatory bowel disease.
炎症性肠病患者患结直肠癌的风险会增加。监测性结肠镜检查尚未显示能延长生存期，且据报道间期癌发生率很高。持续的结肠炎症已被证明在结直肠癌的发生中起重要作用，因此诸如5-氨基水杨酸酯和免疫调节剂等抗炎药物已被视为潜在的化学预防药物。本综述聚焦于已明确显示可降低炎症性肠病患者患结直肠腺瘤和癌症风险的各种化学预防药物。
